Rila Therapeutics, Inc. — Form D
Rila Therapeutics, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2025-01-07. The offering totals $10.8M, of which $7.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-01-07
- Form: D
- Accession: 0002051051-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.8M
- Amount sold: $7.0M
- Remaining: $3.8M
- Investors: 3
- Date of first sale: 2024-12-20
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-534373
Issuer
- Name: Rila Therapeutics, Inc.
- CIK: 0002051051
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 280 UTAH AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Phone: 650-410-5000
Officers, directors & promoters (4)
| Name | Role | Location |
|---|
| William Dai | Director | Malvern, PA |
| Robert Drakas | Director | South San Francisco, CA |
| Michael Hui | Director | New York, NY |
| Robert Drakas | Executive Officer | South San Francisco, CA |
More